Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: Influence of various 7-substituents on antiviral activity

Journal of Medicinal Chemistry

Volumn 39, Issue 4, 1996, Pages 873-880

  Renau, Thomas E ^a   Wotring, Linda L ^b   Drach, John C ^b   Townsend, Leroy B ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRROLO[2,3 D]PYRIMIDINE 5 THIOCARBOXAMIDE DERIVATIVE; ACETIC ACID; FORMIC ACID DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; SANGIVAMYCIN DERIVATIVE; THIOSANGIVAMYCIN; THIOSANGIVAMYCIN DERIVATIVE; TOYOCAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; ZINC;

ALKYLATION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; GROWTH INHIBITION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HYDROGENATION; LEUKEMIA L 1210; MOUSE; NONHUMAN; REDUCTION;

ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; FIBROBLASTS; HERPESVIRUS 1, HUMAN; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PLAQUE ASSAY; PYRIMIDINE NUCLEOSIDES; PYRIMIDINES; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOSIDES; TOYOCAMYCIN;

EID: 0030027845     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950444j     Document Type: Article

References (47)

1. Rubin, R. H. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 1990, 12, S754-S766.
2. Stratta, R. J.; Shaeffer, M. S.; Markin, R. S.; Wood, R. P.; Langnas, A. N.; Reed, E. C.; Donovan, J. P.; Woods, G. L.; Bradshaw, K. A.; Pillen, T. J.; Shaw, B. W., Jr. Cytomegalovirus infection and disease after liver transplantation. Dig. Dis. Sci. 1992, 37, 673-688.
3. Mills, J.; Masur, H. AIDS-related infections. Sci. Am. 1990, 263, 50-57.
4. Peters, B. S.; Beck, E. J.; Anderson, S.; Coleman, D.; Coker, R.; Main, J.; Migdal, C.; Harris, J. R. W.; Pinching, A. J. Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. J. Infect. 1991, 23, 129-137.
5. Davis, M. G.; Kenney, S. C.; Kamine, J.; Pagano, J. S.; Huang, E. S. Immediate early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 8642-8646.
6. Webster, A. Cytomegalovirus as a possible cofactor in HIV disease progression. J. Acquired Immune Defic. Syndr. 1991, 4, S47-S52.
7. Speir, E.; Modali, R.; Huang, E.-S.; Leon, M. B.; Shawl, F.; Finkel, T.; Epstein, S. E. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994, 265, 391-394.
8. Shepp, D. H.; Dandliker, P. S.; de Miranda, P.; Burnette, T. C.; Cederberg, D. M.; Kirk, L. E.; Meyers, J. D. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 1985, 103, 368-373.
9. Collaborative DHPG treatment study group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N. Engl. J. Med. 1986, 314, 801-805.
10. Palestine, A. G.; Polis, M. A.; De Smet, M. D.; Baird, B. F.; Falloon, J.; Kovacs, J. A.; Davey, R. T.; Zurlo, J. J.; Zunich, K. M.; Davis, M.; Hubbard, L.; Brothers, R.; Ferris, F. L.; Chew, E.; Davis, J. L.; Rubin, B. I.; Mellow, S. D.; Metcalf, J. A.; Manischewitz, J.; Minor, J. R.; Nussenblatt, R. B.; Masur, H.; Lane, H. C. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 1991, 115, 665-673.
11. Manischewitz, J. F.; Quinnan, G. V., Jr.; Lane, H. C.; Wittek, A. E. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 1990, 34, 373-375.
12. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med. 1992, 326, 213-220.
13. Jacobson, M. A.; Gambertoglio, J. G.; Aweeka, F. T.; Causey, D. M.; Portale, A. A. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J. Clin. Endocrinol. Metab. 1991, 72, 1130-1135.
14. Deray, G.; Martinez, F.; Katlama, C.; Levaltier, B.; Beaufils, H.; Danis, M.; Rozenheim, M.; Baumelou, A.; Dohin, E.; Gentilini, M.; Jacobs, C. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. 1989, 9, 316-321.
15. Field, A. K.; Biron, K. K. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 1994, 7, 1-13.
16. Erice, A.; Chou, S.; Biron, K. K.; Stanat, S. C.; Balfour, H. H.; Jordan, M. C., Jr. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 1989, 320, 289-293.
17. Sullivan, V.; Coen, D. M. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J. Infect. Dis. 1991, 164, 781-784.
18. Townsend, L. B.; Drach, J. C.; Wotring, L. L.; Vittori, S.; Pudlo, J. S.; Swayze, E. E.; Gupta, P.; Maruyama, T.; Saxena, N.; Coleman, L. A.; Westerman, A. C.; Spurr, J.; Nassiri, M. R.; Turk, S. R.; Krawezyk, S. H. Design, synthesis and studies of the structure activity relationships of certain pyrrolo[2,3-d]-pyrimidine nucleosides and structurally related analogs as potential antineoplastic and antiviral agents. Farmaco 1991, 46, 113-139.
19. Turk, S. R.; Shipman, C., Jr.; Nassiri, M. R.; Genzlinger, G.; Krawezyk, S. H.; Townsend, L. B.; Drach, J. C. Pyrrolo[2,3-d]-pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 1987, 31, 544-550.
20. Renau, T. E.; Ludwig, M. S.; Drach, J. C.; Townsend, L. B. Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin, sangivamycin and thiosangivamycin. Bioorg. Med. Chem. Lett. 1992, 2, 1755-1760.
21. Gupta, P. K.; Daunert, S.; Nassiri, M. R.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis, cytotoxicity and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. J. Med. Chem. 1989, 32, 402-408.
22. Miller, R. L.; Adamczyk, D. L.; Miller, W. H.; Koszalka, G. W.; Rideout, J. L.; Beacham, L. M., III; Chao, E. Y.; Haggerty, J. J.; Krenitsky, T. A.; Elion, G. B. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J. Biol. Chem. 1979, 254, 2346-2352.
23. Glazer, R. I.; Peale, A. L. Comparison between the inhibitory activities of sangivamycin and thiosangivamycin on nuclear ribonucleic acid synthesis in L1210 cells in vitro. Biochem. Pharmacol. 1980, 29, 305-310.
24. Ritch, P. S.; Helmsworth, M. Pyrrolopyrimidine lethality in relation to ribonucleic acid synthesis in Sarcoma 180 cells in vitro. Biochem. Pharmacol. 1982, 31, 2686-2688.
25. Cohen, M. B.; Glazer, R. I. Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells. Mol. Pharmacol. 1985, 27, 349-355.
26. Ritch, P. S.; Glazer, R. I. Preferential incorporation of sangivamycin into ribonucleic acid in Sarcoma 180 cells in vitro. Biochem. Pharmacol. 1982, 31, 259-261.
27. Krawezyk, S. H.; Renau, T. E.; Nassiri, M. R., Westerman, A. C.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus. J. Med. Chem. 1995, 38, 4115-4119.
28. Renau, T. E.; Nassiri, M. R.; Swayze, E. E.; Kern, E. R.; Townsend, L. B.; Brach, J. C. Improved synthesis and biological evaluation of an acyclic thiosangivamycin active against human cytomegalovirus. Antiviral Res. 1992, 19, 15-28.
29. Gupta, P. K.; Nassiri, M. R.; Coleman, L. A.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis, cytotoxicity and antiviral activity of certain 7-[(2-hydroxyethoxy)methyl]pyrrolo-[2,3-d]pyrimidine nucleosides related to toyocamycin and sangivamycin. J. Med. Chem. 1989, 32, 1420-1425.
30. Smee, D. F ; McKernan, P. A.; Alaghamandan, H. A.; Frank, K. B.; Ramasamy, K.; Revankar, G. R.; Robins, R. K. Antiviral activities of 2′-deoxyriboruranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses. Antiviral Res. 1988, 10, 263-278.
31. De Clercq, E.; Balzarini, J.; Madej, D.; Hansske, F.; Robins, M. J. Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J. Med. Chem. 1987, 30, 481-486.
32. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
33. Tanaka, H.; Baba, M.; Saito, S.; Miyasaka, T.; Takashima, H.; Sekiya, K.; Ubasawa, M.; Nitta, I.; Walker, R. T.; Nakashima, H.; De Clercq, E. Specific Anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 1991, 34, 1508-1511.
34. Romero, D. L.; Busso, M.; Tan, C.-K.; Reusser, F.; Palmer, J. R.; Poppe, S. M.; Aristoff, P. A.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8806-8810.
35. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
36. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Gaul, S. L.; Saari, W. S.; Wai, J. S.; Hoffman, J. M.; Anderson, P. S.; Hupe, D. J.; Emini, E. A.; Stern, A. M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
37. Smee, D. F.; Bartlett, M. L.; Alaghamandan, H. A.; Jones, M. M.; Revankar, G. R.; Robins, R. K. 4,6-Dibenzamidopyrazolo-[3,4-d]pyrimidine is a highly selective inhibitor of cytomegalovirus adsorption to cells. Antiviral Res. 1990, 13, 1-10.
38. Kelley, J. L.; Linn, J. A.; Krochmal, M. P.; Selway, J. W. T. 9-Benzyl-6-(dimethylamino)-9H-purines with antirhinovirus activity. J. Med. Chem. 1988, 31, 2001-2004.
39. Swayze, E. E.; Hinkley, J. M.; Townsend, L. B. 2-Amino-5-bromo-3,4-dicyanopyrrole. In Nucleic acid chemistry; improved and new synthetic procedures, methods and techniques, Part IV; Townsend, L. B., Tipson, R. S., Eds.; Wiley-Interscience: New York, 1991; pp 16-18.
40. Ramasamy, K.; Robins, R. K.; Revankar, G. R. Total synthesis of 2′-deoxytoyocamycin, 2′-deoxysangivamycin and related 7-β-D-arabinofuranosylpyrrolo[2,3-d]pyrimidines via ring closure of pyrrole precursors prepared by the stereospecific sodium salt glycosylation procedure. Tetrahedron 1986, 42, 5869-5878.
41. Tolman, R. L.; Robins, R. K.; Townsend, L. B. Pyrrolopyrimidine nucleosides. III. The total synthesis of toyocamycin, sangivamycin, tubercidin and related derivatives. J. Am. Chem. Soc. 1969, 91, 2102-2108.
42. Taylor, E. C.; Hendess, R. W. Synthesis of 4-amino-5-cyanopyrrolo[2,3-d]pyrimidine, the aglycone of toyocamycin. J. Am. Chem. Soc. 1964, 86, 951-952.
43. Hinshaw, B. C.; Gerster, J. F.; Robins, R. K.; Townsend, L. B. Pyrrolopyrimidine nucleosides. V. A study of the relative chemical reactivity of the 5-cyano group of the nucleoside antibiotic toyocamycin and desaminotoyocamycin. The synthesis of analogs of sangivamycin. J. Org. Chem. 1970, 35, 236-241.
44. Renau, T. E.; Lee, J. S.; Kim, H.; Young, C. G.; Wotring, L. L.; Townsend, L. B.; Drach, J. C. Relationship between cytotoxicity and conversion of thiosangivamycin analogs to toyocamycin analogs in cell culture medium. Biochem. Pharmacol. 1994, 48, 801-807.
45. Wotring, L. L.; Townsend, L. B. Study of the cytotoxicity and metabolism of 4-amino-3-carboxamido-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine using inhibitors of adenosine kinase and adenosine deaminase. Cancer Res. 1979, 39, 3018-3023.
46. Prichard, M. N.; Shipman, C., Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14, 181-206.
47. Prichard, M. N.; Prichard, L. E.; Baguley, W. A.; Nassiri, M. R.; Shipman, C., Jr. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob. Agents Chemother. 1991, 35, 1060-1065.